Evidence map›Paper›PMID 40631887›Full record

ArticleJournal of clinical microbiology2025

Comparative performance of cobas 4800 HPV Test and Anyplex II HPV HR for high-risk human papillomavirus detection.

Luani R Godoy, Mariam El-Zein, Elizaveta Padalko, Bo Verberckmoes, Bodine Van Eenooghe, Heleen Vermandere, Sónia Dias, Ana Gama, Bernardo Vega Crespo, Vivian Alejandra Neira and 3 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Luani R Godoy *Division of Cancer Epidemiology, McGill University, Montreal, Québec, Canada.ORCID 0000-0002-1559-293X
Mariam El-Zein *Division of Cancer Epidemiology, McGill University, Montreal, Québec, Canada.
Elizaveta PadalkoDepartment of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
Bo VerberckmoesInternational Centre for Reproductive Health, Department of Public Health and Primary Care, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
Bodine Van EenoogheInternational Centre for Reproductive Health, Department of Public Health and Primary Care, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
Heleen VermandereInternational Centre for Reproductive Health, Department of Public Health and Primary Care, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
Sónia DiasNOVA National School of Public Health, Public Health Research Centre, Comprehensive Health Research Center (CHRC), LA-REAL, NOVA University Lisbon, Lisbon, Portugal.
Ana GamaNOVA National School of Public Health, Public Health Research Centre, Comprehensive Health Research Center (CHRC), LA-REAL, NOVA University Lisbon, Lisbon, Portugal.
Bernardo Vega CrespoFacultad de Ciencias Médicas, Universidad de Cuenca, Cuenca, Ecuador.
Vivian Alejandra NeiraDepartment of Biosciences, Faculty of Chemical Sciences, University of Cuenca, Cuenca, Ecuador.
Eduardo L FrancoDivision of Cancer Epidemiology, McGill University, Montreal, Québec, Canada.ORCID 0000-0002-4409-8084
Adhemar Longatto-FilhoMolecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.ORCID 0000-0002-5779-9752
ELEVATE Study Group

Funding

Fundação de Amparo à Pesquisa do Estado de São Paulo 2018/220176Fundação de Amparo à Pesquisa do Estado de São Paulo 2020/00445-6, 2022/00712-0Horizon 2020 Framework Programme 825747
6 · The paper itself

Abstract

Numerous molecular tests are available to detect human papillomavirus (HPV). We compared the analytical performance of cobas and Anyplex for detection of high-risk (HR) carcinogenic HPV genotypes, assessed the composition of HPV types (other than 16 and 18) that influenced cobas performance, and considered the impact of viral load on test performance. We used data from the Early Detection of Cervical Cancer in Hard-to-Reach Populations of Women Through Portable and Point-of-Care HPV Testing project, which involved collection (2019-2022) of cervicovaginal samples from 1,042 women aged 21-74 years in Belgium (

Indexed as

Molecular Diagnostic TechniquesPapillomaviridaePapillomavirus InfectionsAdultAgedBelgiumBrazilCervix UteriEarly Detection of CancerEcuadorFemaleGenotypeHuman Papillomavirus VirusesHumansMiddle AgedPortugalAnyplex II HPV HR assaycobas 4800 HPV testhuman papillomavirusperformance

Identifiers

PMID40631887
PMCPMC12345211

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.